A comprehensive understanding of the molecular mechanisms underlying multiple myeloma (MM) pathogenesis is essential for developing therapeutic strategies that overcome disease heterogeneity and treatment relapse. In this review, we focus on transcription factors (TFs), key regulators of gene expression that play critical roles in normal hematopoiesis and MM biology. We first discuss the physiological functions of TFs in lymphoid lineage commitment and terminal B‐cell differentiation into plasma cells. This provides insights into the contribution of key TFs, such as IRF4 and PRDM1, to development of MM. We then examine the regulatory mechanisms of TFs in MM, exploring how their deregulation participates in the pathogenesis of the disease. We summarize the roles of major TF families, highlighting both well‐established TFs essential for MM pathogenesis and emerging TFs with potential clinical relevance. In addition to their functional roles, several TFs show promise as biomarkers for patient stratification and risk assessment. Finally, we discuss recent advances that challenge the notion of TFs as “undruggable”, including siRNA‐loaded lipid nanoparticles or Proteolysis‐Targeting Chimeras (PROTACs), which offer novel opportunities to therapeutically modulate TF activity. These strategies could enable the development of novel interventions aimed at improving clinical outcomes and quality of life for MM patients. Collectively, this review integrates physiological and pathological insights into TF function in MM and underscores their potential as biomarkers and actionable targets in precision medicine.
In previous research, we created a C. elegans model with homozygous mutations in calreticulin similar to those found in patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF), two myeloproliferative neoplasms (MPNs). This model, lacking JAK orthologs, enabled us to examine the transcriptomic effects caused by mutant calreticulin without the influence of JAK/STAT activation, the primary pathogenic mechanism associated with calreticulin mutations known to date. Most of the gene expression changes observed seemed to be due to a partial loss of protein function, with the alteration of the extracellular matrix being particularly notable. In this study, our aim was to determine whether this model exhibited any phenotype related to these transcriptomic alterations. The results demonstrate that these strains exhibit multiple phenotypes related to the alteration of the extracellular matrix, fat levels, and fertility, which could be a possible consequence of a partial loss of calreticulin function. These phenotypes resemble some of the clinical and molecular characteristics described in patients with MPNs, but they had never before been linked to a loss of protein function in humans. Thus, these results collectively suggest that CALR mutations could have significant effects on MPNs due to loss of protein function. Delving deeper into these effects to develop innovative therapies for these patients offers considerable potential and interest, given that targeted therapies for these patients have not yielded very promising results so far.